SAB Biotherapeutics (NASDAQ:SABS) Stock Price Up 0.6% – Here’s Why

SAB Biotherapeutics, Inc. (NASDAQ:SABS) shot up 0.6% on Wednesday . The company traded as high as $3.67 and last traded at $3.62. 368,862 shares traded hands during mid-day trading, a decline of 56% from the average session volume of 835,619 shares. The stock had previously closed at $3.60.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on SABS shares. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of SAB Biotherapeutics in a research report on Monday, June 15th. Rodman & Renshaw restated a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Barclays started coverage on shares of SAB Biotherapeutics in a report on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price objective on the stock. Leerink Partners raised their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Chardan Capital upped their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, June 17th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.00.

SAB Biotherapeutics Trading Up 0.6%

The company has a current ratio of 11.45, a quick ratio of 11.45 and a debt-to-equity ratio of 0.01. The stock has a market cap of $276.79 million, a P/E ratio of -1.72 and a beta of 0.52. The business’s fifty day simple moving average is $3.73 and its 200 day simple moving average is $3.85.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, analysts expect that SAB Biotherapeutics, Inc. will post -1.19 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the 1st quarter worth approximately $29,000. ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at about $30,000. Dimensional Fund Advisors LP acquired a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at approximately $32,000. State of Wyoming bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth $34,000. Finally, Virtu Financial LLC bought a new position in SAB Biotherapeutics during the third quarter worth about $40,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.